FDA Approves Abbott's Novel Dissolvable Stent Therapy for Peripheral Artery Disease
HCPLive
APRIL 29, 2024
Abbott's Esprit BTK System was shown to significantly reduce risk of ischemic events in patients with PAD versus angioplasty over 1 year.
HCPLive
APRIL 29, 2024
Abbott's Esprit BTK System was shown to significantly reduce risk of ischemic events in patients with PAD versus angioplasty over 1 year.
Med Page Today
APRIL 29, 2024
(MedPage Today) -- The FDA approved the Esprit BTK everolimus-eluting scaffold system for chronic limb-threatening ischemia (CLTI) below the knee, Abbott announced on Monday. This system represents the first drug-eluting resorbable scaffold with.
DAIC
APRIL 11, 2024
The study, called IVUS-DCB, is the first randomized controlled trial to demonstrate the clinical benefits of using IVUS in angioplasty procedures for peripheral artery disease (PAD), a condition in which plaque builds up in arteries in the legs. The study was funded by Medtronic, Inc. and Korea United Pharm.
The American Journal of Cardiology
APRIL 9, 2025
Publication date: Available online 8 April 2025 Source: The American Journal of Cardiology Author(s): Subhash Banerjee, David Fernandez Vazquez, Yu-Lun Liu, Sameh Sayfo, Minseob Jeong, Zachary P. Rosol, Anand Gupta, Blake M. Bruneman, Sarah G. Weideman, Kennedy S. Adelman, Shirling Tsai, Shuaib Abdullah, Hung B. Chu, Bertram L. Smith, Bradley R.
AMS Cardiology
NOVEMBER 4, 2023
However, when these arteries become narrowed or blocked conditions like Peripheral Artery Disease (PAD) can emerge, posing a threat to our overall health. Understanding Peripheral Artery Disease Peripheral artery disease or PAD is a condition in which plaque builds up in the arteries that lead to the legs and feet.
DAIC
MARCH 14, 2025
Some of the late-breaking topics that will be covered include transcatheter aortic valve replacement (TAVR), peripheral artery disease (PAD), and pulmonary embolism (PE): Impact of Age on Procedural Timing for Asymptomatic Severe Aortic Stenosis: Results from the Early TAVR Trial The PERFORMANCE II Trial: A Prospective Multicenter Single Arm Investigation (..)
DAIC
JULY 11, 2024
a Mountain View, CA-based developer of novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), has announced the appointment of Josh Smale as its Vice President of Global Clinical and Scientific Affairs. Medical device company R3 Vascular Inc., Image courtesy: R3 Vascular Inc.
Let's personalize your content